The study did not meet the primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48. Topline data were announced from a phase 3 trial evaluating efzofitimod in ...

Please provide your email address to receive an email when new articles are posted on . A greater proportion of patients receiving efzofitimod vs. placebo were steroid-free with a stable/improved King ...

Prednisone is recommended as the first-line treatment for pulmonary sarcoidosis, but this steroid causes a number of unwanted side effects. Now new research published at the ATS 2025 International ...

Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters ...

Please provide your email address to receive an email when new articles are posted on . Various efzofitimod doses given to patients with pulmonary sarcoidosis were well tolerated. Lung function and ...

(RTTNews) - aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, on Wednesday announced that it will present three important posters on efzofitimod at the American Thoracic Society or ATS ...

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine ...

The mean change in the percentage of FVC from baseline to week 24 was 6.75 and 6.11 percentage points in the prednisone and methotrexate groups, respectively. HealthDay News — For patients with ...

Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosis Further development of namilumab for the treatment of sarcoidosis will be discontinued Primary Endpoint Details: ...

BASEL, Switzerland & LONDON & NEW YORK--(BUSINESS WIRE)--Roivant (Nasdaq: ROIV) and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and ...

Prednisone is recommended as the first-line treatment for pulmonary sarcoidosis, but this steroid causes a number of unwanted side effects. Now new research, published at the ATS 2025 International ...